GV-971 + MEMANTINE for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Jun 2022: Trial registered, NCT05430867

The trials

NCT05430867: Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

State
State not given
Phase
Phase 4
People
150 planned
Started
1 Jul 2022
Primary completion
1 Jul 2024
Arms
Memantine combined with GV-971 group
Results
None posted
  1. 24 Jun 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.